《艾昆纬（IQVIA）：2025放射配体疗法：新加坡癌症治疗的未来白皮书（英文版）（26页）.pdf》由会员分享，可在线阅读，更多相关《艾昆纬（IQVIA）：2025放射配体疗法：新加坡癌症治疗的未来白皮书（英文版）（26页）.pdf（26页珍藏版）》请在三个皮匠报告上搜索。

1、White PaperRadioligand Therapy as the Future of Cancer Care in SingaporeAUGUST 2025LUKE WILLBOURN,Principal,Strategy Consulting,IQVIASMITHA SREEDHARAN,Associate Director,Medical Writing,IQVIASTEVEN SURJA,Consultant,Strategy Consulting,IQVIAADIVITIYA BIHAGARA,Medical Writer 2,RWE Medical and Scientif

2、ic Writing,IQVIATable of contentsOverview 1Executive summary 2Value of radioligand therapy 3Current status of PSMA+mCRPC in Singapore 4Current landscape of RLT in Singapore assessment of readiness and identified gaps 6Stakeholder awareness 6Clinical research on RLT 6Infrastructure for RLT 8Regulator

3、y framework for RLT 10Funding scheme for RLT 12Potential solutions case studies from different countries 13A call to action 15References 18About the authors 22About the contributors and observers 23 |1Prostate cancer(PC)represents a significant and growing public health concern in Singapore,currentl

4、y ranking as the most commonly diagnosed cancer among males.The burden of disease is expected to grow substantially in the coming years,driven by demographic aging and shifting lifestyle-related risk factors.Amid this growing burden,nuclear medicine is transforming cancer care by enabling precise di

5、agnostics and targeted therapies.Radioligand Therapy(RLT),particularly Lutetium-177(Lu-177)-based prostate-specific membrane antigen(PSMA)-targeted agents,has emerged as a promising and transformative approach in the management of metastatic Castration-Resistant Prostate Cancer(mCRPC).Nationally,PC

6、prevalence is projected to reach 18,000 cases by 2040.A considerable proportion of these will progress to advanced stages,including mCRPC,for which conventional treatment options remain limited and patient outcomes often suboptimal.Nuclear medicine is transforming cancer care by allowing precise dia